a 204

A 204 is a polycyclic polyether monocarboxylic acid antibiotic isolated from fermentation of strain of Streptomyces albus.

Jagged-1 (188-204) TFA(219127-21-6 free base) is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-alphaB activation.

DT204 is an SCFSkp2 inhibitor that reduces the binding of Skp2 to Cullin-1 and Commd1. It can be used to study multiple myeloma.

ICI 204,448 is a potent κ-opioid agonist with potential analgesic activity for the study of neurological diseases.

ODM-204 is a novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme (IC50s of 80 nM and 22 nM, respectively).

Anticanceragent 204 (Compound 6) is a fluorinated derivative of cinnamamides with anticancer activity. It can arrest the cell cycle of HepG2 cells in the G1 phase and induces apoptosis by reducing mitochondrial membrane polarization (MMP) levels.

Antitumor agent-204 (compound 15a) is a potent antitumor drug with cytotoxic properties. It induces the release of nitric oxide (NO) and the production of reactive oxygen species (ROS). Additionally, Antitumor agent-204 triggers apoptosis and causes cell cycle arrest at the G2/M phase, demonstrating significant antitumor activity.

CRBN ligand-204 is an E3 ubiquitin ligase cereblon (CRBN) ligand, which functions to recruit cereblon proteins. CRBN ligand-204 can be linked to a target protein ligand via a linker to form a PROTAC.

EGFR-IN-204 (Example 1) is a selective inhibitor targeting HER2 exon 20 mutations, with a preference for wild-type EGFR. It exhibits antiproliferative effects on cells dependent on the HER2 exon 20 YVMA insertion mutation and wild-type HER2, showing greater selectivity compared to cells dependent on wild-type EGFR. EGFR-IN-204 is applicable in non-small cell lung cancer research.

NLX-204 is a selective, potent agonist of ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor with pKi value of 10.19.

NLX-204 hydrochloride is a potent and selective ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor agonist(pKi = 10.19).

LK 204-545 is a highly selective antagonist of beta1-adrenoceptor.

BSJ-03-204 is a rationally designed PROTAC composed of cereblon and CDK ligands that functions as a potent and selective palbociclib-based CDK4/6 dual degrader, achieving nanomolar inhibition of CDK4/D1 and CDK6/D1 complexes without inducing IKZF1/3 degradation, BSJ-03-204 exhibit strong anticancer activity with improved selectivity.

Sdz 204-090 is a cyclic octapeptide analog of somatostatin.

BAY-204 is a CSNK1α/δ inhibitor that can be used in the treatment of proliferative diseases.

GC-204 is a selective inhibitor of carbonic anhydrase ix (caix)

BSJ-03-204 triTFA is a potent and selective Cereblon- and CDK-targeted PROTAC (PROteolysis TArgeting Chimera) featuring Palbociclib-based ligands for the degradation of CDK4/6. It exhibits IC50 values of 26.9 nM for CDK4/D1 and 10.4 nM for CDK6/D1, indicating strong inhibitory capabilities. Notably, it spares IKZF1/3 from degradation and possesses anti-cancer activity [1].

Antibacterial agent 204 (Compd P2-56-3) enhances the activity of Rifampin (RIF) against Acinetobacter baumannii and Klebsiella pneumoniae by disrupting the outer membrane of A. baumannii. T [1].

Jagged-1 (188-204)is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-αB activation.

BFC204 is an inhibitor of SARS-CoV-2 Mpro, with a kinact/Ki value of 619 mol/s.

ML204 is a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels.

ML204 hydrochloride (ML204 HCl) is a selective and potent TRPC4/TRPC5 channel antagonist that blocks TRPC4β currents activated by intracellular dialysis via μ-opioid receptor stimulation or guanosine 5'-3-O-(thio)trisphosphate (GTPgammaS).

MK204 is an inhibitor of AKR1B10, a tumor marker and promising antineoplastic target.

MT204 is a humanized IgG1 antibody inhibitor that targets IL-2 from human and rhesus monkey sources. It prevents soluble IL-2 from binding to the intermediate-affinity IL-2 receptor and blocks IL-2 bound to CD25 from interacting with the high-affinity IL-2 receptor. In rhesus monkey allogeneic skin transplant models, MT204 shows excellent tolerability and potent immunosuppressive activity. With linear pharmacokinetics, a reasonable serum half-life, and signs of good safety and efficacy, MT204 holds promise for use in immunotherapy.